- Home
- / Dechra Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Dechra Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
£38.7
2024-01-15
Market Capitalization
£44 M
2024-01-15
Revenue
£761.5 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 407.1M | 481.8M | 515.1M | 608.0M | 681.8M | 761.5M |
| Cost of goods sold | 177.3M | 122.1M | 139.7M | 171.4M | 206.2M | 176.4M |
| Gross profit | 229.8M | 359.7M | 375.4M | 436.6M | 475.6M | 585.1M |
| Gross profit margin, % | 56.4% | 74.7% | 72.9% | 71.8% | 69.8% | 76.8% |
| Operating expense total | 132.3M | 232.3M | 238.0M | 252.7M | 281.9M | 407.1M |
| Depreciation and amortization | 61.5M | 86.6M | 83.8M | 90.7M | 90.8M | 158.8M |
| EBITDA | 97.2M | 127.0M | 137.1M | 182.8M | 192.4M | 177.1M |
| EBITDA margin, % | 23.9% | 26.4% | 26.6% | 30.1% | 28.2% | 23.3% |
| EBIT | 35.7M | 40.7M | 53.3M | 91.8M | 102.3M | 18.2M |
| EBIT margin, % | 8.8% | 8.4% | 10.3% | 15.1% | 15.0% | 2.4% |
| Interest income | 200.0K | 100.0K | 100.0K | 800.0K | ||
| Interest expense | 6.4M | 11.5M | 14.0M | 9.8M | 12.2M | 44.5M |
| Pre tax profit | 28.9M | 27.8M | 40.9M | 74.0M | 77.6M | (36.1M) |
| Income tax expense | (7.2M) | (3.1M) | 7.0M | 18.5M | 19.4M | (8.2M) |
| Net Income | 36.1M | 30.9M | 33.9M | 55.5M | 58.2M | (27.9M) |